ETON
Eton Pharmaceuticals, Inc. · Healthcare · Market cap $1.4B
Insiders sold $12.0M net in the last 90 days ·4 sellers, 0 buyers· latest Form 4 filed Oct 6, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$25.4M
reported sales (SEC code S)
Unique Insiders
5
in the rolling window
Latest filing
Oct 6, 2026
Krempa David
Eton Pharmaceuticals, Inc. (ETON) has 21 SEC Form 4 filings (52 transaction rows) in the rolling window, disclosed by 5 distinct insiders. Most recent filing: Oct 6, 2026.
Inside the rolling window, 5 insiders at Eton Pharmaceuticals, Inc. reported no open-market purchases and 14 open-market sales totaling $25.4M. The most active filer is Chief Business Officer Krempa David with 5 filings. Insiders have net sold $25.4M over the trailing 6 months. The most recent open-market filing is a sale of 4,166 shares by Chief Business Officer Krempa David, dated Oct 6, 2026, worth $229K.
- Industry:Drug Manufacturers - Specialty & Generic
- CEO:Sean E. Brynjelsen
- Employees:44
- HQ:Deer Park, IL, US
- IPO:2018-11-14
| Source | |||||||
|---|---|---|---|---|---|---|---|
| Chief Business Officer | Sale | 4,166 | $229K | Oct 6 | -10.0% | SEC ↗ | |
| Director | Sale | 50,000 | $3.0M | Aug 31 | -18.4% | SEC ↗ | |
| Chief Business Officer | Sale | 25,000 | $1.6M | Aug 24 | -23.5% | SEC ↗ | |
| President & CEO | Sale | 8,978 | $562K | Aug 20 | -17.7% | SEC ↗ | |
| President & CEO | Sale | 91,022 | $5.5M | Aug 20 | -17.7% | SEC ↗ | |
| 10% Owner | Sale | 28,315 | $1.1M | Jul 17 | — | SEC ↗ | |
| 10% Owner | Sale | 90,000 | $3.4M | Jul 7 | — | SEC ↗ | |
| 10% Owner | Sale | 10,000 | $380K | Jul 7 | — | SEC ↗ | |
| 10% Owner | Sale | 26,685 | $1.0M | Jul 7 | — | SEC ↗ | |
Adams Jennifer McKieFirst filing | Director | Sale | 50,000 | $1.6M | Jun 17 | — | SEC ↗ |
BRYNJELSEN SEANFirst filing | President & CEO | Sale | 120,000 | $3.8M | May 29 | — | SEC ↗ |
Krempa DavidFirst filing | Chief Business Officer | Sale | 42,797 | $1.4M | May 27 | — | SEC ↗ |
Krempa DavidFirst filing | Chief Business Officer | Sale | 37,524 | $1.2M | May 27 | — | SEC ↗ |
Krempa DavidFirst filing | Chief Business Officer | Sale | 19,679 | $619K | May 27 | — | SEC ↗ |
Earnings: last 7 quarters
Congress trading ETON 1 all-time
- DRep. Thomas SuozziPurchase$15,001 - $50,0002022-10-11
STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.
Frequently asked questions
How many SEC Form 4 insider filings does ETON have?
Eton Pharmaceuticals, Inc. (ETON) has 21 SEC Form 4 filings (52 transaction rows) in the rolling 365-day window, disclosed by 5 distinct insiders. Most recent filing: Oct 6, 2026.
When was the most recent SEC Form 4 filing for ETON?
The most recent Form 4 filing for ETON on Tracefour is dated Oct 6, 2026.
Who is the most active insider at ETON?
The most active SEC Form 4 filer at ETON in the rolling window is Chief Business Officer Krempa David, with 5 filings.
What is the net insider flow at ETON over the last 6 months?
Over the trailing 180 days, insiders at ETON have net sold $25.4M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at ETON in the current window?
Inside the rolling window, insiders at ETON bought $0 and sold $25.4M based on SEC Form 4 filings.
Can I get alerts for ETON insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Eton Pharmaceuticals, Inc. (ETON). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Eton Pharmaceuticals, Inc. is in the Healthcare sector.